Evidence map›Paper›PMID 41542776›Full record

ArticleThe Journal of clinical investigation2026

Helping alveolar macrophages live to fight another day during viral pneumonia.

Elise Mr Armstrong, Joseph P Mizgerd

Abstract readComment
In one paragraph

Article in The Journal of clinical investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Elise Mr ArmstrongPulmonary Center.
Joseph P MizgerdPulmonary Center.

Funding

Fibrin in the Infected LungR01HL171499 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI JOSEPH P MIZGERD · 2024 to 2026
$2.3M
Lung interstitial macrophage remodeling during and after recovery from pneumococcal respiratory infectionF31HL178234 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Elise Armstrong · 2025 to 2026
$100k
NHLBI NIH HHS F31 HL178234NHLBI NIH HHS R01 HL171499
6 · The paper itself

Abstract

Alveolar macrophages (AMs) help defend the lungs against infection, but during pneumonia many alveolar macrophages die. In this issue of the JCI, Malainou et al. explored the mechanism underpinning AM death during viral pneumonia and its effect on the outcomes of bacterial superinfection, a secondary infection that occurs before the first infection is cleared. In mouse models of influenza A infection, recruited neutrophils secreted TNF superfamily member 14 (TNFSF14), and AMs increased expression of the TNFSF14 receptors TNFSFR14 and type I transmembrane lymphotoxin β receptor (LTβR). TNFSF14 signaling via the LTβR was sufficient to cause AM apoptosis. TNFSF14 deficiency or blockade preserved AMs during influenza infection and diminished bacterial burdens and mouse mortality during pneumococcal superinfection. The adoptive transfer of AMs decreased the severity of pneumococcal superinfections, if those AMs lacked the LTβR. Thus, preserving AMs by interrupting TNFRSF14-LTβR interactions can make virus-infected lungs less susceptible to severe bacterial superinfection.

Indexed as

Macrophages, AlveolarPneumonia, ViralAnimalsApoptosisHumansLymphotoxin beta ReceptorMiceSignal TransductionSuperinfectionTumor Necrosis Factor Ligand Superfamily Member 14Ltbr protein, mouseLymphotoxin beta ReceptorTumor Necrosis Factor Ligand Superfamily Member 14

Identifiers

PMID41542776
PMCPMC12807482

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.